{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:57:49Z","timestamp":1790485069096,"version":"4.1.0"},"reference-count":30,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:00:00Z","timestamp":1598832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      In a previous clinical study, the authors evaluated the potential of antitenascin C monoclonal antibody (mAb) 81C6 labeled with\n                      <jats:sup>211<\/jats:sup>\n                      At via the prosthetic agent\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      -succinimidyl 3-[\n                      <jats:sup>211<\/jats:sup>\n                      At]astatobenzoate (SAB) for the treatment of primary brain tumors. Although encouraging results were obtained, labeling chemistry failed while attempting to escalate the dose to 370\u2009MBq. The goal of the current study was to develop a revised procedure less susceptible to radiolysis-mediated effects on\n                      <jats:sup>211<\/jats:sup>\n                      At labeling that would be suitable for use at higher activity levels of this \u03b1-emitter.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      Addition of\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      -chlorosuccinimide to the methanol used to remove the\n                      <jats:sup>211<\/jats:sup>\n                      At from the cryotrap after bismuth target distillation was done to thwart radiolytic decomposition of reactive\n                      <jats:sup>211<\/jats:sup>\n                      At and the tin precursor. A series of 11 reactions were performed to produce SAB at initial\n                      <jats:sup>211<\/jats:sup>\n                      At activity levels of 0.31\u20132.74 GBq from 50\u2009\u03bcg of\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      -succinimidyl 3-trimethylstannylbenzoate (Me-STB), which was then reacted with murine 81C6 mAb without purification of the SAB intermediate. Radiochemical purity, immunoreactive fraction, sterility, and apyrogenicity of the\n                      <jats:sup>211<\/jats:sup>\n                      At-labeled 81C6 preparations were evaluated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Murine 81C6 mAb was successfully labeled with\n                      <jats:sup>211<\/jats:sup>\n                      At using these revised procedures with improved radiochemical yields and decreased overall synthesis time compared with the original clinical labeling procedure.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      With 2.74 GBq of\n                      <jats:sup>211<\/jats:sup>\n                      At, it was possible to produce 1.0 GBq of\n                      <jats:sup>211<\/jats:sup>\n                      At-labeled 81C6 with an immunoreactive fraction of 92%. These revised procedures permit production of\n                      <jats:sup>211<\/jats:sup>\n                      At-labeled mAbs suitable for use at clinically relevant activity levels.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cbr.2019.3204","type":"journal-article","created":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T16:40:20Z","timestamp":1582908020000},"page":"511-519","source":"Crossref","is-referenced-by-count":6,"title":["Labeling Monoclonal Antibody with \u03b1-emitting\n                    <sup>211<\/sup>\n                    At at High Activity Levels via a Tin Precursor"],"prefix":"10.1177","volume":"35","author":[{"given":"Ganesan","family":"Vaidyanathan","sequence":"first","affiliation":[{"name":"Department of Radiology, Duke University Medical Center, Durham, North Carolina, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar R.","family":"Pozzi","sequence":"additional","affiliation":[{"name":"Department of Radiology, Duke University Medical Center, Durham, North Carolina, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaeyeon","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Radiology, Duke University Medical Center, Durham, North Carolina, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Guang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Radiology, Duke University Medical Center, Durham, North Carolina, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Murphy","sequence":"additional","affiliation":[{"name":"Department of Radiology, Duke University Medical Center, Durham, North Carolina, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Zalutsky","sequence":"additional","affiliation":[{"name":"Department of Radiology, Duke University Medical Center, Durham, North Carolina, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,8,31]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2015.12.003"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.2174\/1874471011104040283"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.109.062604"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2015.07.005"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.107.046938"},{"key":"e_1_3_6_7_2","first-page":"1508","article-title":"High-level production of alpha-particle-emitting 211At and preparation of 211At-labeled antibodies for clinical use","volume":"42","author":"Zalutsky MR","year":"2001","unstructured":"Zalutsky MR, , Zhao XG, , Alston KL, et al. High-level production of alpha-particle-emitting 211At and preparation of 211At-labeled antibodies for clinical use. J Nucl Med, 2001; 42:1508.","journal-title":"J Nucl Med"},{"key":"e_1_3_6_8_2","first-page":"700","article-title":"Radiopharmaceutical chemistry of targeted radiotherapeutics, part 1: Effects of solvent on the degradation of radiohalogenation precursors by 211At alpha-particles","volume":"46","author":"Pozzi OR","year":"2005","unstructured":"Pozzi OR, , Zalutsky MR. Radiopharmaceutical chemistry of targeted radiotherapeutics, part 1: Effects of solvent on the degradation of radiohalogenation precursors by 211At alpha-particles. J Nucl Med, 2005; 46:700.","journal-title":"J Nucl Med"},{"key":"e_1_3_6_9_2","first-page":"1393","article-title":"Radiopharmaceutical chemistry of targeted radiotherapeutics, part 2: Radiolytic effects of 211At alpha-particles influence N-succinimidyl 3-211At-astatobenzoate synthesis","volume":"46","author":"Pozzi OR","year":"2005","unstructured":"Pozzi OR, , Zalutsky MR. Radiopharmaceutical chemistry of targeted radiotherapeutics, part 2: Radiolytic effects of 211At alpha-particles influence N-succinimidyl 3-211At-astatobenzoate synthesis. J Nucl Med, 2005; 46:1393.","journal-title":"J Nucl Med"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.106.038505"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2016.11.009"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2006.99"},{"key":"e_1_3_6_13_2","first-page":"133","article-title":"Monoclonal antibody localization in subcutaneous and intracranial human glioma xenografts: Paired-label and imaging analysis","volume":"4","author":"Bourdon MA","year":"1984","unstructured":"Bourdon MA, , Coleman RE, , Blasberg RG, et al. Monoclonal antibody localization in subcutaneous and intracranial human glioma xenografts: Paired-label and imaging analysis. Anticancer Res, 1984; 4:133.","journal-title":"Anticancer Res"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1215\/15228517-2007-053"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(84)90435-6"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00153635"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0969-8051(97)00060-7"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0969-8051(98)00120-6"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1010951013855"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0883-2889(89)90131-7"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.18.7149"},{"key":"e_1_3_6_22_2","first-page":"4719","article-title":"Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate","volume":"54","author":"Zalutsky MR","year":"1994","unstructured":"Zalutsky MR, , McLendon RE, , Garg PK, et al. Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate. Cancer Res, 1994; 54:4719.","journal-title":"Cancer Res"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.107.049833"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep12025"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2017.00366"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.5b00664"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon.13.7"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-014-9618-3"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3621"},{"key":"e_1_3_6_30_2","unstructured":"Chen J Zhu A. Mapping the drug conjugation sites of an antibody-drug conjugate. Agilent Technologies Application Note. 2015:5991-6389EN."},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2014.1729"}],"container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cbr.2019.3204","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cbr.2019.3204","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cbr.2019.3204","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:15:32Z","timestamp":1777385732000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cbr.2019.3204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,31]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1089\/cbr.2019.3204"],"URL":"https:\/\/doi.org\/10.1089\/cbr.2019.3204","relation":{},"ISSN":["1084-9785","1557-8852"],"issn-type":[{"value":"1084-9785","type":"print"},{"value":"1557-8852","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,31]]}}}